In today's Pharmaceutical Executive Daily, FDA approves AstraZeneca's Fasenra as a new treatment for hypereosinophilic ...

According to him, the industry must address its relationship with the capital markets, address misinformation issues, and push back against the politicization of medical research and development.

Toragen is uniquely positioned to navigate this dynamic. Its HPV E5 inhibitor addresses indications that span both sexes: HPV-positive head and neck cancer affects predominantly men, cervical cancer ...

Hypereosinophilic syndrome is defined by persistent eosinophilia with eosinophil-mediated organ/tissue damage, driving ...

In today's Pharmaceutical Executive Daily, the FDA grants accelerated approval to BeOne Medicines' Beqalzi as the first and only BCL2 inhibitor for relapsed or refractory mantle cell lymphoma, while ...

In the first part of her interview with Pharmaceutical Executive, Sandra Coufal, MD, CEO of Toragen, explains why the HPV E5 ...

Accelerated approval of sonrotoclax establishes a targeted BCL2 option in post–BTK inhibitor relapsed/refractory mantle cell lymphoma, a setting with limited effective salvage therapies and poor ...

The current prior authorization (PA) process is an administrative failure. Beyond the excessive time and paperwork required, ...

Phase IIIb SURMOUNT-Maintain showed near-complete weight-loss maintenance on maximum tolerated tirzepatide through Week 112, while a 5 mg step-down dose was associated with 5.6 kg mean regain.

White House sources indicate Trump approved Makary’s removal, reflecting escalating senior leadership churn across federal health agencies. Makary’s tenure featured MAHA-aligned regulatory positions, ...

Veppanu leverages PROTAC-mediated ubiquitin–proteasome degradation to eliminate mutant estrogen receptor, aiming to bypass ESR1-driven endocrine resistance rather than merely inhibiting receptor ...

Madrigal Pharmaceuticals entered an exclusive global license agreement with Arrowhead Pharmaceuticals for ARO-PNPLA3, a ...